A phase I trial with the CCR5 antagonist maraviroc in patients with liver metastases of advanced refractory CRC showed mitigation of the tumor‐promoting microenvironment and objective tumor responses (NCT01736813).319. The gene discussed is CCR5; the disease is colorectal carcinoma.